Mark Delaney: Okay, Juniper, I have to tell you — I was reading this approval news on Monday morning and I had to stop and re-read the date three times because July 7th, 2026, the FDA greenlights Trutakna for IgA nephropathy and I'm just like — wait, this is Vera Therapeutics' first product ever. Ever.
Juniper Vale: First commercial product, yeah. Brisbane, California company.
Mark Delaney: And the drug blocks two targets at once — BAFF and APRIL, both simultaneously — which, I mean, that's the pitch. Dual blockade. But here's where I got stuck. The approval wasn't on kidney function. It was on proteinuria reduction. A surrogate endpoint.
Juniper Vale: Right — but let me back up for a second, because not everyone is going to know why IgAN is the disease you don't want to get and then just be left with blood pressure meds. This is the most common primary glomerular disease globally. It quietly destroys kidneys. And until about five years ago there was nothing targeted at the actual mechanism.
Mark Delaney: Nothing. So a drug that blocks BAFF and APRIL, which are the cytokines driving the whole pathogenic process — that's not a small thing.
Juniper Vale: It's not. And yet — the FDA approved Trutakna on UPCR reduction, not on eGFR, not on evidence the kidneys are actually holding on. That data from the ORIGIN 3 trial is still coming.
Mark Delaney: So patients get access now, but the proof that their kidneys are actually surviving — that's still out there somewhere waiting.
Juniper Vale: That's the tension sitting at the center of this whole story.
Mark Delaney: Okay but — the tension is real, I just want to understand *what* is actually new here. Because dual blockade sounds impressive until you remember Otsuka's already on the market hitting APRIL alone.
Juniper Vale: Think of it like this — your immune system in IgAN has two faucets feeding the flood. Most drugs shut off one. Trutakna shuts off both at the same time. That's the whole thing. That's what a TACI-Fc fusion protein actually does — it's a molecular decoy that intercepts both BAFF and APRIL before they can activate the B-cells making the bad antibodies.
Mark Delaney: Two faucets. Got it.
Juniper Vale: And the on-target evidence is actually there — ORIGIN 3, 431 patients, showed a 68% reduction in Gd-IgA1. That's the pathogenic antibody that deposits in the kidney glomeruli. Sixty-eight percent. That's not the drug doing something vague, that is the mechanism visibly working.
Mark Delaney: Huh — sixty-eight percent on the actual bad antibody, not just a downstream marker. Okay, that's a real number.
Juniper Vale: It is. And the UPCR data from ORIGIN 3 — 42% placebo-adjusted reduction at 36 weeks — that's, I mean, those are the strongest proteinuria numbers we've seen in IgAN. But here's where I want to be careful, because there's a difference between the mechanism working and the mechanism mattering for a patient's kidneys over twenty years.
Mark Delaney: So the headline — 'first dual-target blockade' — that's real science, but we're uh, we're kind of comparing it to Otsuka's single-APRIL drug without actually knowing if two faucets beats one faucet in the long run?
Juniper Vale: Exactly — because eGFR, the actual kidney-function measure, isn't back yet. So right now it's genuinely apples to oranges. The mechanism is distinct, the biomarker data is real, but clinical superiority over a single-target approach? That's still an open question.
Mark Delaney: Which means the headline's doing work the data hasn't done yet.
Juniper Vale: And that's exactly the wrong take I keep seeing — 'accelerated approval means the FDA has seen enough, this drug works.' That framing is just flatly misleading.
Mark Delaney: Yeah, I mean — who's saying that specifically?
Juniper Vale: It's everywhere in the biotech coverage. The approval was on UPCR reduction — that's a surrogate. Proteinuria going down is a signal, not proof that kidneys are surviving longer. The confirmatory eGFR data from ORIGIN 3 aren't expected until Q3 2026. Patients can start injecting this weekly before that evidence exists.
Mark Delaney: Okay but — wait, isn't there precedent for this? Like, Calliditas Therapeutics did the same thing with Tarpeyo back in 2021. First IgAN-specific accelerated approval, also on a surrogate.
Juniper Vale: Tarpeyo set the playbook, yeah. Calliditas got there first. But that precedent being established doesn't mean the logic gets cleaner every time someone follows it — if anything, the accelerated approval pathway is under active policy scrutiny right now. Repeating a contested framework doesn't validate it.
Mark Delaney: Right — and the supplemental BLA for full traditional approval isn't even filed until Q4 2026, so we're talking about patients on this drug for potentially months before anyone formally closes that evidentiary gap. That's uh, that's a real window where the clinical story is incomplete.
Juniper Vale: Which brings me to the part that doesn't get said enough — Vera didn't invent this molecule. They in-licensed atacicept from Merck KGaA roughly six years before this approval. So the question of who actually benefits from accelerated timing isn't purely about patients.
Mark Delaney: Huh. So Trutakna is Vera's first commercial product ever, they licensed it from Merck KGaA, and the approval they needed to stay viable as a company lands on a surrogate endpoint. I'm not saying that's cynical, I'm just — that's a structural fact about who the timing helps.
Juniper Vale: Patient access, or biotech survival runway — and when those Q3 eGFR numbers land, we'll find out which framing was doing the heavier lift. That's the question clinicians are going to have to answer at the bedside, and we'll get into what that actually looks like for a real patient.
Mark Delaney: And that bedside conversation — I keep picturing some forty-two-year-old who just got the IgAN diagnosis, at-risk-of-progression, sitting across from a nephrologist who now has six approved options on the table. Six. Tarpeyo, Otsuka's APRIL inhibitor, the Novartis offering, Trutakna — I mean, how does a doctor even start that conversation?
Juniper Vale: With the side-effect math, probably. Because with Trutakna specifically — 150 milligrams, subcutaneous, once weekly, self-administered autoinjector — you're asking someone to commit to that routine potentially for decades. And the infection signal in ORIGIN 3 was 32% on Trutakna versus 28% on placebo.
Mark Delaney: Four points. That sounds small.
Juniper Vale: It sounds small until you run it out over ten years of weekly injections. Four percentage points of absolute infection risk — that's not a footnote, that's a recurring cost your immune system is paying every year you're on this drug.
Mark Delaney: Okay, and then the injection-site reactions — uh, I saw 30% versus 5% on placebo. That's not four points. That is a different order of thing entirely.
Juniper Vale: Yeah, 30% versus 5% is a clinically meaningful tolerability gap. That's one in three patients dealing with something at the injection site — and look, most of those aren't serious, but picture that forty-two-year-old pulling out an autoinjector every Saturday morning for the next twenty years. At some point the burden is real.
Mark Delaney: Which is — I mean, that's the comparison a nephrologist actually has to make against what Otsuka's single-APRIL drug is showing, right? Because if the tolerability profile there is cleaner and you're only hitting one target instead of two, some doctors are just gonna go with what they know.
Juniper Vale: And that's exactly why the Q3 eGFR data from ORIGIN 3 is the whole ballgame for Vera Therapeutics. If dual blockade — BAFF and APRIL simultaneously — unambiguously slows kidney function decline better than single-target competitors, then the mechanism story earns its keep. If those numbers come back inconclusive, Vera's trying to entrench a market position on an unfinished clinical story with five competitors already dug in.
Mark Delaney: And Trutakna is their only product. Their whole commercial future is one Q3 readout. That's — yeah, that's a lot riding on one data drop.
Juniper Vale: And the uncomfortable version of that question — the one I keep not being able to shake — is whether mechanism innovation alone is enough. Like, a TACI-Fc decoy that hits both BAFF and APRIL is genuinely elegant science. The Gd-IgA1 reduction, the proteinuria numbers. That's real. But is that enough for a patient to switch off something that's already working? That's a different question than 'is this drug good.'
Mark Delaney: Yeah, and that's — I mean, Q3 either closes that gap or it doesn't. And if the eGFR data come back anything less than clearly better, I genuinely don't know how Vera makes that case against Calliditas or Otsuka or Novartis. Five competitors, one data readout, no fallback product.
Juniper Vale: That Q3 number will answer something bigger than Trutakna's market position, too. It'll say something about whether the FDA's accelerated pathway in nephrology is actually calibrated right — whether surrogate endpoints are doing the job they're supposed to do. That's the part I'll be watching.
Mark Delaney: Yeah. And we won't know for a few months. Which is kind of where we have to leave it.
Juniper Vale: Genuinely open question. Thanks for working through it.
